… landscape include Hepatocellular carcinoma (HCC), Non-small cell lung cancer (NSCLC), Gastric cancer, and potentially other … the Report Hepatocellular carcinoma (HCC), Non-small cell lung cancer (NSCLC), Gastric cancer, and others Key …

… in the treatment of NSCLC. This initiative is made … in the treatment of NSCLC with EGFR mutations including … promising new approaches for treating Non-Small Cell Lung Cancer. These grants provide the … Early-Stage Atypical EGFR-Mutant NSCLC (ADAPT-A) “This …

… the post-operative diagnosis was non-small cell lung cancer; (3) patients with complete … in patients with resectable non-small cell lung cancer (NSCLC). The study found that … for sleeve lobectomy within non-small cell lung cancer. Thorac Cancer. 2024; …

… non–small cell lung cancer (NSCLC). He also highlighted the comprehensive …  exon 20 insertion mutation–positive NSCLC, as well as for use … assay, and thus, patients with NSCLC may require additional or alternative …

… predict how patients with advanced NSCLC will respond to immunotherapy. … predict how patients with advanced non-small cell lung cancer (NSCLC) will respond to immunotherapy, … responses in patients diagnosed with NSCLC, offering promising potential for …

Panelists discuss how real-world experience with amivantamab plus lazertinib has shown remarkable responses consistent with trial data, including effectiveness in challenging cases such as leptomeningeal disease, with manageable adverse effects when proper …

… tumors of patients with non-small cell lung cancer (NSCLC) to shrink less than … revolutionary for patients with NSCLC, the authors wrote, … therapy in patients with NSCLC.1 The investigators enrolled … 30–89 years) with NSCLC who initiated treatment between …

… –small cell lung cancer (NSCLC). The AIM-HIGH trial … stage IA, IB, or IIA NSCLC following surgical resection. Traditionally, … oncology in early-stage NSCLC and may pave the … chemotherapy for stage IA-IIA non-small cell lung cancer identified as high-risk …

Panelists discuss how resistance mechanisms in ALK-positive disease are driving development of next-generation inhibitors like NVL-655 that spare TRK to reduce neurocognitive toxicity while targeting compound resistance mutations, though the success of …

… inhibitors. Treatment of EGFRm NSCLC is evolving, with combination … EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes … line EGFR-mutant advanced NSCLC treated with amivantamab plus … in EGFR-mutant advanced NSCLC after disease progression on …